These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 12468176)

  • 1. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium.
    Holcomb K; Delatorre R; Pedemonte B; McLeod C; Anderson L; Chambers J
    Obstet Gynecol; 2002 Dec; 100(6):1290-5. PubMed ID: 12468176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
    Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
    Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
    Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
    Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas.
    Yalta T; Atay L; Atalay F; Caydere M; Gonultas M; Ustun H
    J Int Med Res; 2009; 37(1):163-8. PubMed ID: 19215686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
    Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
    Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
    Schlosshauer PW; Ellenson LH; Soslow RA
    Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD44 expression in papillary serous endometrial carcinoma.
    Hosford S; Elliott J; Ma ZW; Majeste R; Dubeshter B
    Int J Gynecol Cancer; 2003; 13(4):480-4. PubMed ID: 12911725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation.
    Martinez AA; Weiner S; Podratz K; Armin AR; Stromberg JS; Stanhope R; Sherman A; Schray M; Brabbins DA
    Gynecol Oncol; 2003 Sep; 90(3):537-46. PubMed ID: 13678721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
    Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
    Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes.
    Kallakury BV; Ambros RA; Hayner-Buchan AM; Sheehan CE; Malfetano JH; Ross JS
    Int J Gynecol Pathol; 1998 Oct; 17(4):320-6. PubMed ID: 9785132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women.
    Matthews RP; Hutchinson-Colas J; Maiman M; Fruchter RG; Gates EJ; Gibbon D; Remy JC; Sedlis A
    Gynecol Oncol; 1997 May; 65(2):206-12. PubMed ID: 9159326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
    Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
    Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological findings in early-stage endometrial cancer.
    Zehavi S; Schneider D; Bukovsky I; Halperin R
    Eur J Gynaecol Oncol; 2003; 24(1):18-20. PubMed ID: 12691310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
    González-Rodilla I; Aller L; Llorca J; Muñoz AB; Verna V; Estévez J; Schneider J
    Anticancer Res; 2013 Nov; 33(11):5091-5. PubMed ID: 24222154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications.
    Aquino-Parsons C; Lim P; Wong F; Mildenberger M
    Gynecol Oncol; 1998 Oct; 71(1):83-6. PubMed ID: 9784324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes.
    Alkushi A; Köbel M; Kalloger SE; Gilks CB
    Int J Gynecol Pathol; 2010 Jul; 29(4):343-50. PubMed ID: 20567148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
    Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
    BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.